RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Abstract Background KRAS is the most frequently mutated oncogene in human cancers, with KRASG12C being a prevalent driver mutation in 12–13% non-small cell lung cancer (NSCLC) cases. Despite breakthroughs in KRASG12C inhibitors such as sotorasib (AMG-510) and adagrasib (MRTX-849), clinical resistanc...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Jianzhuang Wu, Kexin Xie, Yixuan Zhang, Weiyi Zhang, Rongjie Cheng, Yaliang Zhang, Yugui Xia, Tongyan Liu, Rong Yin, Yudong Qiu, Tao Xu, Rutian Li, Qi Sun, Chao Yan
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2025-03-01
Serie:	Journal of Experimental & Clinical Cancer Research
Ämnen:	RASON KRAS Non-small cell lung cancer Immune evasion CD47
Länkar:	https://doi.org/10.1186/s13046-025-03369-9
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!